Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a narrative review article synthesizing conceptual frameworks about noncoding RNA roles in cancer immunity; it raises questions and proposes theoretical connections rather than presenting original empirical evidence or meta-analysis of existing trials.
Registry record for an observational cohort study with recruitment completed but results not yet published; describes planned analysis of associations between pre-diagnosis GLP-1 RA use and post-cancer mortality in a large administrative database.
This is a narrative review synthesizing current knowledge of photodynamic therapy applications in veterinary medicine, offering evidence-based guidance on mechanisms, clinical uses, and future directions, though the authors explicitly note that existing clinical evidence is limited by very small sample sizes and absence of comparator groups.
Large, well-designed population-based case-crossover study with clear effect sizes and confidence intervals showing independent association between RBC transfusion and venous thrombosis in cancer patients after adjustment for confounders.
A prospective national cohort study with adequate sample size and multivariable analysis showing a significant association between childhood violence exposure and adult cancer risk, but relying on self-reported outcomes and a single exposure assessment, limiting causal inference.
This is a completed observational registry study with no reported results; it describes methods for collecting sensor data from cancer patients to assess symptoms, but outcomes have not yet been published or registered.
This is a narrative review synthesizing emerging applications of AI in extracellular vesicle research; it raises mechanistic and translational questions rather than reporting original empirical results or clinical outcomes.
This is a Phase 1 dose-escalation trial registration with no reported results; it is designed to establish safety and recommended phase 2 dose, with preliminary efficacy assessment as secondary aims.